EC
PTGX icon

EntryPoint Capital’s Protagonist Therapeutics PTGX Stock Holding History

EntryPoint Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,696
Closed -$84.7K – 1693
2023
Q4 		$84.7K Buy
+3,696
New +$64.7K 0.08% 463

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

EntryPoint Capital's PTGX Position: Q1 2024 in Review

EntryPoint Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2024, closing a stake of 3,696 shares — an estimated $84.7K sold.

EntryPoint Capital first reported a position in PTGX in Q4 2023 and held it in 1 quarter. The position peaked at $84.7K in Q4 2023. 185 funds tracked by Wall St. Rank hold PTGX as of Q1 2024.

  • EntryPoint Capital reported no remaining Protagonist Therapeutics position as of Q1 2024 after selling out during the quarter.
  • EntryPoint Capital sold 3,696 Protagonist Therapeutics shares in Q1 2024, an estimated $84.7K.
  • EntryPoint Capital first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 1 quarter.
  • EntryPoint Capital's Protagonist Therapeutics position peaked at $84.7K in Q4 2023.
  • 185 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.